• News
  • SAN DIEGO
  • BioTech

FDA accepts NDA submission for carbamazepine IV

Ligand Pharmaceuticals Inc.'s Captisol licensee Lundbeck LLC announced that the FDA has accepted for review a new drug application for its investigational therapy intravenous carbamazepine.

To continue reading, subscribe now
or
log in to your account
User Response
0 UserComments

Ligand Pharmaceuticals

Company Website

11085 N. Torrey Pines Rd. Ste., 300
La Jolla, CA 92037

Company Trade Data

Stock Symbol Close
Change
Chg %Chg
Volume
52-Week
High Low
LGND
54.13
  3.46  
+ 6.83%
495,749,000
80.42
41.99

Insider Trade Data

Date Insider Shares Type Value
10/15/2014 Kozarich, John W 2,000 Purchase $91,360
10/15/2014 Kozarich, John W 2,000 Purchase $91,360
10/13/2014 Foehr, Matthew W 1,000 Exchange $9,970
10/13/2014 Foehr, Matthew W 1,000 Exchange $9,970
10/10/2014 Foehr, Matthew W 85 Purchase $3,817

Ligand Pharmaceuticals Executive(s):

John Higgins

  • Chief Executive Officer, President

Similar Companies

NAICS - 325412 - Pharmaceutical Preparation Manufacturing
SIC - 2834 - PHARMACEUTICAL PREPARATIONS
SIC - 2835 - IN VITRO AND IN VIVO DIAGNOSTIC SUBSTANCES
NAICS - 541711 - Research and Development in Biotechnology
SIC - 8731 - COMMERCIAL PHYSICAL AND BIOLOGICAL RESEARCH
SIC - 8733 - NONCOMMERCIAL RESEARCH ORGANIZATIONS
Subscribe Today!